(NASDAQ: AVTE) Aerovate Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.59%.
Aerovate Therapeutics's earnings in 2025 is -$48,960,000.On average, 2 Wall Street analysts forecast AVTE's earnings for 2025 to be -$854,295,755, with the lowest AVTE earnings forecast at -$1,159,400,760, and the highest AVTE earnings forecast at -$549,190,749. On average, 2 Wall Street analysts forecast AVTE's earnings for 2026 to be -$477,997,745, with the lowest AVTE earnings forecast at -$691,570,959, and the highest AVTE earnings forecast at -$264,424,531.
In 2027, AVTE is forecast to generate -$711,912,646 in earnings, with the lowest earnings forecast at -$711,912,646 and the highest earnings forecast at -$711,912,646.